



RESI
CONFERENCE

REDEFINING
EVERY STAGE
OF INVESTMENT
SEED TO EXIT

LONDON 2025



DEC 4 | LONDON, UK
DEC 8-9 | VIRTUAL PARTNERING

PRESENTED BY



**LIFE SCIENCE
NATION**

Connecting Products, Services & Capital

ONSITE GUIDE

Capital investors, licensing partners, fundraising CEOs, and
service providers

Make a Compelling Connection

CO-DEVELOPMENT PARTNER

TITLE SPONSOR



RESIConference.com | 11 Cavendish Square

#RESI #RESILONDON



RESI

2026 CONFERENCE SERIES



RESI JPM 2026

JAN 12-13: SAN FRANCISCO MARRIOTT MARQUIS
JAN 14, 19 & 20: VIRTUAL PARTNERING



RESI EUROPE 2026

MAR 23: LISBON, PORTUGAL
MAR 24-25: VIRTUAL PARTNERING



RESI JUNE 2026

JUNE 22: SAN DIEGO, CA
JUNE 23-24: VIRTUAL PARTNERING



RESI BOSTON 2026

SEPT 22-23: BOSTON, MA
SEPT 25, 28: VIRTUAL PARTNERING

For more information about our future events, visit our website RESIConference.com or contact us at RESI@lifesciencenation.com.

CONTENT

RESI LONDON 2025

Welcome to RESI	1
Floor Plan	4
RESI Agenda	5
Sponsors & Exhibitors	6
Investor Panels	10
Innovator's Pitch Challenge	17
Entrepreneur's Workshops	25

WELCOME



Welcome to RESI London

Life Science Nation and our co-development partner, One Nucleus welcome you to RESI London at the King's Fund. RESI brings together early-stage innovators, investors, and licensing partners to create meaningful connections that help new technologies reach the market.

Early-stage companies succeed through strong international relationships. London's global hub status and One Nucleus' leadership across the UK and Europe make this the ideal environment for productive partnering.

What RESI Offers

- **1-on-1 Partnering** – LSN's matching engine connects companies with investors, licensing groups, and partners by stage and product type. Curated meetings and ongoing networking provide a focused environment for productive first conversations and future collaborations.
- **Investor Panels** – Investors and industry leaders share insights on trends, evaluation, and opportunities.
- **Innovator's Pitch Challenge (IPC)** – IPC showcases founders presenting live to investor judges, with interactive RESI Cash voting.
- **Workshops** – Practical guidance on fundraising, valuation, global roadshows, and partnering strategy.

Building Long-Term Connections

RESI recognises that early-stage fundraising and business development are long-cycle processes. A single conference can spark months of dialogue, diligence, and collaboration. The structured format is designed to support focused first meetings and sustained follow-up.

Partnership with One Nucleus

RESI London is delivered in collaboration with One Nucleus, whose work connecting institutions, companies, and ecosystem builders strengthens the region's global reach and supports the innovators and investors who participate.

Sponsors and Partners

- **Co-Development Partner:** One Nucleus
- **Title Sponsor:** Biometas
- **Silver Sponsor:** Mosaic Biosciences
- **Bronze Sponsor:** DLRC
- **Exhibitors:** Certara, Ontario Economic Development, Biotech Gate

We Look Forward to Seeing You at RESI London

We look forward to a dynamic, relationship-driven day that supports your company's growth, your investment thesis, and the advancement of early-stage innovation worldwide.

Sougato Das

President and Chief Operating Officer
Life Science Nation



TUESDAY, DECEMBER 2ND, 1-5 PM

LSN Fundraising Bootcamp at London Bio-Innovation Week 2025

Life Science Nation hosts a fundraising bootcamp as part of London Bio Innovation Week. This half day session provides early stage executives with practical guidance on preparing for a global partnering campaign. Topics include story development, investor landscape, global target list creation, and the mechanics of structured outreach. Participants receive tools they can immediately apply to their fundraising programs.

- Date & Time: Tuesday, December 2nd | 1:00 PM – 5:00 PM
- Location: Fieldfisher Law Firm, Riverbank House, 2 Swan Lane, London
- Cost: Free

This interactive half-day workshop brings together industry experts, investors, and fundraising professionals to share practical insights and actionable strategies for your next raise.

Agenda Highlights:

- It All Starts with The Story
- Global Partnering Campaign – Investor Landscape, GTL & GPC
- LSN Event Partnering Process
- Maximizing the Power of your Pitch
- Shark Tank Session (Company Pitch)

Don't miss this opportunity to strengthen your fundraising skills and network with key players in the global life science ecosystem.

Presenters:




Dennis Ford

Founder & CEO
Life Science Nation



Greg Mannix

VP, International BD
Life Science Nation



Karen Deyo

VP of Product, Israel BD
Life Science Nation

Free Sign Up



**LIFE SCIENCE
NATION**

Connecting Products, Services & Capital

Contact us at resi@lifesciencenation.com


WEDNESDAY, DECEMBER 3RD

RESI London attendees are invited to take part in Genesis 2025 Session 4 and the closing reception. This collaboration with One Nucleus reflects our shared commitment to strengthening the regional ecosystem and expanding access to global networks.

- Date & Time: Wednesday, December 3rd | 4:10 – 6:45 PM
- Location: 1 Wimpole Street, London, UK
- Cost: Free (Genesis 2025 Session 4 & Drinks Reception)

SESSION 4

- 16:10-16:30 • **Fireside Chat – What Has Surprised Us Most in the Past 25 Years?**
 - **Olivia Cavlan**, LifeArc Ventures
 - **Nick Bastin**, Optimum Strategic Communications
- 16:30-16:50 • **Fireside Chat – What Comprises an Innovation-friendly Environment?**
 - **Marco Delise**, Stevenage Bioscience Catalyst
 - **Pedro Correa de Sampaio**, Neobe Therapeutics
- 16:50-17:30 • **Keynote Panel: Has the Past 25 Years of Life Sciences R&D Delivered on Expectations?**
 - What was the ambition in year 2000?
 - Was it achieved?
 - If not, why not?
 - What provides optimism by 2050?
 - Moderator: **Mike Ward**, Clarivate
 - Panellists: **Priya Mande**, RNAvate, **Anne Lane**, UCL Business, **Madeleine Wakeling**, Harness Therapeutics, **Hayley French**, Domainex
- 17:30-17:40 • **Closing Remarks**
Tony Jones
- 17:40 • **Drinks Reception**
- 18:45 • **Close**




Sponsors & Exhibitors

- 1 One Nucleus
- 2 Ontario Ministry of Economic Development
- 3 BioMetas
- 4 Life Science Nation
- 5 Mosaic Biosciences
- 6 Certara
- 7 Venture Valuation (Biotech Gate)
- 8 DLRC

Pitching Company Posters

- | | | |
|---|--------------------------------|-------------------|
| 1 BDUK Therapeutics | 15 Olavide Neuron STX (ONESTX) | 21 Ysium Medical |
| 2 Immune Macro Biotic Technology UK Ltd | 16 MEDTECH CATALONIA / CLYPE | 22 Dyogel |
| 3 Keyron | 17 Breath Predict | 23 Interlinked AB |
| 4 Diamante Società Benefit srl | 18 ALLOGENICA | 24 myotwin |
| 5 4C Biomed | 19 HEPHAISTOS | 25 MindLab |
| 6 Oxolife | 20 ONCOVITA | |
| 7 BIOCAPTIVA LTD | | |
| 8 Immunokey | | |
| 9 Sania Tx | | |
| 10 Lovaltech | | |
| 11 Oncolize | | |
| 12 Drug4Sight | | |
| 13 BRIGHT BIOTECH | | |
| 14 STRATISAL | | |



THURSDAY, DECEMBER 4TH - RESI LONDON

Time: Wednesday, December 4th, 9AM - 5PM
Location: King's Fund - 11 Cavendish Square

WIFI: 11Cavendishsq
Password: brickred

9:00 AM – 5:00 PM: Onsite Partnering (Burdett Suite)

Investor Panels
(Maynard Theatre)

Innovator's Pitch Challenge
(Maynard 2)

Entrepreneur's Workshops
(Maynard 1)

9:00 AM
-
9:50 AM

PARTNERING WITH BIG PHARMA
Building Strategic Relationships to Accelerate Innovation

SESSION #1
THERAPEUTICS

 **mosaic**
Accelerating Early-Stage Drug Discovery

10:00 AM
-
10:50 AM

ANGELS & FAMILY OFFICES
Flexible Capital and Long-Term Support for Early-Stage Innovators

SESSION #2
DIAGNOSTICS TOOLS & PLATFORMS

 **one nucleus**
Life science investment landscape: continuing the conversation

11:00 AM
-
11:50 AM

MEDICAL DEVICES & DIAGNOSTICS
Forward Looking Trends in MedTech Innovations

SESSION #3
THERAPEUTICS

fieldfisher
On Good Terms: Getting to terms with Term Sheets

12:00 - 1:00 PM: Lunch Break (Orangery)

 **LIFE SCIENCE NATION**
Connecting Products, Services & Capital
LSN BD ASSIST
Your Global Matching and Partnering Engine

1:00 PM
-
1:50 PM

DIGITAL HEALTH & AI
Harnessing Technology to Transform the Patient Journey

SESSION #4
THERAPEUTICS & MEDICAL DEVICES

TALES FROM THE ROAD
Biotech and MedTech Innovators on their Fundraising Journey

2:00 PM
-
2:50 PM

UK / EUROPE ECOSYSTEM
Global Opportunities in a Dynamic Innovation Landscape

SESSION #5
THERAPEUTICS

CERTARA
Designing a smarter regulatory path to First in Human (FIH) studies

3:00 PM
-
3:50 PM

EARLY STAGE THERAPEUTICS
Accelerating Breakthrough Therapies in Pre-Clinical and Early Clinical Stages

SESSION #6
MEDICAL DEVICES

 **DLRC**
Navigating Regulatory Pathways for Early-Stage Innovation

4:00 PM
-
4:50 PM

SEED FUNDS
Catalyzing the Earliest Stages of Healthcare Innovation

SESSION #7
R&D AND ENABLING TECHNOLOGIES

 **VENTURE VALUATION**
GLOBAL VALUATION SERVICES
Company Valuation for Fundraising

5:00 - 7:00 PM: Cocktail Reception (Orangery) - IPC Winners Announced

SPONSORS & EXHIBITORS

ORGANIZER



CO-DEVELOPMENT PARTNER



TITLE SPONSOR



SILVER SPONSOR



BRONZE SPONSOR



EXHIBITORS



SPONSORS & EXHIBITORS



Table #1

**CO-DEVELOPMENT
PARTNER**

One Nucleus is a not-for-profit Life Sciences & Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector providing local, UK-wide and international connectivity. Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.



Table #3

TITLE SPONSOR

BioMetas: Supporting the Next Generation of Therapeutic Startups

BioMetas is a trusted partner for early-stage biotech innovators, providing a comprehensive suite of preclinical research services. With expertise spanning in vitro biology, in vivo pharmacology, cancer biology, protein science, and immunology, BioMetas enables startups to progress their drug development programs efficiently. By streamlining the preclinical process and providing milestone-driven support, BioMetas helps biotech companies de-risk their assets and position them for successful global partnering opportunities.



Table #5

SILVER SPONSOR

Mosaic is a protein and antibody discovery company that helps its partners identify next-generation therapies for the prevention and treatment of disease. Mosaic teams provide comprehensive, end-to-end discovery services, including program assessment and strategy development; program management; antibody discovery and optimization; protein production, purification, and characterization; protein engineering; biochemical and cellular assay development; formulation, stability and developability studies; bioanalytical (PK and PD) assay development; and clinical candidate-validating pharmacology. Mosaic partners include biopharmaceutical companies, startup companies, and University seed and venture capital funds. For more information, please visit www.mosaicbio.com

SPONSORS & EXHIBITORS



Table #8

BRONZE SPONSOR

The pathway to market is complex, but DLRC makes it simpler. With offices in the UK, Germany, and the US, and over 1,000 years of combined regulatory experience, we support clients from top pharma to start-ups with strategies covering the full lifecycle of medicinal products and medical devices. Our expert team has served 130+ companies worldwide, offering global regulatory advice, gap analysis, expedited pathways, EU CTR transition planning, and health authority engagement, as well as managing clinical trial applications, marketing authorisations, medical writing, and lifecycle operations. We also provide representation as US agent, EU authorised/legal representative, and SME/ODD/MAH holder. Recognised with the King's Award for Enterprise and TOPRA Regulatory Excellence, DLRC is a trusted partner for maximising product potential.



Table #6

EXHIBITOR

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more www.certara.com.



Table #2

EXHIBITOR

Ontario is taking life sciences to the next level, tackling some of the biggest challenges the world has ever seen. In 2022, the province released a comprehensive strategy to establish Ontario as a global biomanufacturing and life sciences hub leading the development, commercialization and early adoption of innovative health products and services. With investments of \$3 billion, our diversified sector, collaborative spirit and deep talent pool are creating medical innovations that will improve health care delivery around the globe. Whether you want to expand your operations here or source some of the highest quality medical products and services in the world, Ontario is your life sciences destination.



Table #7

EXHIBITOR

Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 69,000 life science company profiles. Thanks to its unique data sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for life sciences start-ups, pharma companies, investors, and other industry professionals. Biotechgate also features 30,000 licensing deals and a clinical trials database containing over 800,000 records from registries around the world.

RESI CONFERENCE SERIES PRESENTED BY LIFE SCIENCE NATION



**LIFE SCIENCE
NATION**

Connecting Products, Services & Capital

Table #4

Life Science Nation (LSN)

Life Science Nation has built a global partnering backbone that links early stage healthcare companies with capital investors and licensing partners. Our resources combine data, technology, education, and curated events to help innovators prepare for and execute global fundraising and partnering campaigns.

Key Resources

- GPC Platform + RESI Conference Series: Match with investors and partners by product, stage, and allocation needs across Drugs, Devices, Diagnostics, and Digital Health.
- Partner Network: Includes service providers, tech hubs, and agencies that power early-stage life sciences.
- Three Components: Investor & Licensing Partner Database integrated with Salesforce CRM, RESI Partnering Events, and Entrepreneurial Education.



**Global
Partnering
Campaign**

Global Partnering Campaign (GPC)

The GPC combines LSN's investor/licensing database with Salesforce CRM. Subscribers receive a vetted Global Target List (GTL) of likely partners organized into priority tiers:

- Tier 1: Exact mandate fit
- Tier 2: Opportunistic investors seeking compelling assets
- Tier 3: Potential fits based on recent activity

Profiles update daily and integrate with CRM to track outreach, materials shared, notes, and investor pipeline reporting.



LSN BD ASSIST

LSN BD Assist

BD Assist is LSN's managed global outreach program. We build and refine your global target list, integrate it into Salesforce CRM, develop messaging, launch coordinated outreach, and manage meeting scheduling. This enables founders to focus on development while we manage the time consuming work of investor engagement.

What BD Assist Delivers

- AI-optimized messaging for outreach
- Prioritized partner targeting
- Coordinated outreach campaigns
- Confirmed investor meetings synced to your CRM

With over a decade of experience teaching startups how to craft their story and secure funding, LSN combines trusted methodology with hands-on execution. Results speak for themselves: 90% of companies in our Australian accelerator cohort secured funding or partnerships.

If you're raising capital or licensing in the next 12 months, BD Assist is your turnkey solution for launching a global campaign without building an in-house BD team.

Contact us at salescore@lifesciencenation.com to get started.




**LIFE SCIENCE NATION
PUBLICATIONS**

LSN Publications

LSN publishes educational content and market insights to support early stage companies as they prepare for global fundraising. These publications highlight investor trends, partnering strategies, and best practices for telling a clear and compelling story.

NEXT PHASE»



9:00 AM | PARTNERING WITH BIG PHARMA

Building Strategic Relationships to Accelerate Innovation

Large pharmaceutical companies remain key players in the healthcare ecosystem, often providing the resources, global reach, and expertise needed to bring breakthrough innovations to market. For early-stage companies, forging the right partnerships with big pharma can validate their science, accelerate product development, and unlock access to broader commercialization pathways.

This 50-minute panel will highlight how startups and established pharma companies collaborate across licensing, R&D partnerships, co-development deals, and strategic investments. Panelists will share insights on what pharma seeks in potential partners, how these relationships are structured, and the role of corporate venture arms in supporting innovation. Learn how to navigate these partnerships to create win-win opportunities that drive therapies forward to patients worldwide.

Oliver Sexton, Investment Director, Future Planet Capital (Moderator)



Oliver is an Investment Director at UKI2S. Specialising in life science investments he has managed the enlarged £33m engineering biology sub-fund since its inception in 2014. He has invested in a broad range of companies in sectors as diverse as therapeutic, agritech and clean biotech. He sits on multiple boards and has overseen exits including the £85m sale of Quethera to Astellas. He is also a member of the Future Planet Capital ESG steering group. Prior to joining UKI2S, Oliver worked at the venture fund Imperial Innovations as well as other roles in the industry. He has a background in strategy analysis and consultancy including roles in New York and has a masters from the University of Bristol and commenced a PhD in bioremediation at the University of Nottingham.

Semra Kitchen, Senior Director, Search & Evaluation, R&I, AstraZeneca



Semra Kitchen is a Senior Director in the Respiratory and Immunology S&E team with the Business Development group at AstraZeneca. Prior to her role at AZ Semra was a Director in the Search and Evaluation team for Specialty Medicine at GSK. During her tenure, she played key roles in significant projects, including the Bellus Health acquisition for the chronic cough medicine Camlipixant, and the asset acquisition of the CD19/CD20 T cell engager from Chimagen Biosciences. Semra holds a PhD in Cellular Immunology from the London School of Hygiene and Tropical Medicine and has substantial experience as a matrix leader for drug discovery programs-spanning both large and small molecules - with a particular focus on autoimmune medicines and managing external partnerships.

Richard Taylor, Executive Director BD, European Innovation Hub Transaction, MSD



Richard Taylor is Executive Director of Business Development at MSD's European Innovation Hub, leading licensing, acquisition, and collaboration transactions across early to late-stage assets. With over 20 years of global pharmaceutical BD experience, he directs evaluation and due diligence teams, guides market analysis, and negotiates complex agreements. Richard has delivered partnerships spanning therapeutics, platform technologies, discovery collaborations, and spin-outs. Before MSD, he held senior roles at Strike Pharma AB, Actura Bioscience Consulting, Sobi, and Eisai.

Samuel Black, Director, BD Neurology and Immunology, Merck Group



Sam Black is a Business Development & Licensing professional at Merck with 8+ years of life sciences experience in Europe, APAC and the US. He has executed numerous transactions, leading international, cross-functional, project teams on negotiations primarily across oncology, immuno-oncology, neurology, and immunology. He has broad experience across deal types and structures (e.g. in and out-licensing of assets and technologies, collaboration agreements, option agreements, asset acquisitions, academic partnerships, combination agreements, and companion diagnostic agreements) including corporate components of such transactions (e.g.: equity considerations), up to deal values of \$2B+. Sam holds a MPhil in Bioscience Enterprise from the University of Cambridge and a MEng in Biochemical Engineering with Management from University College London.

Matthew Brown, Senior Director, Alliance Management, GSK



Matthew Brown is a Senior Director in Alliance Management within GSK's R&D Business Development organisation, overseeing key alliances that support GSK's research and development priorities. Based in the UK, he plays a central role in shaping and implementing M&A integration approaches across the R&D landscape. Over eight years at GSK, Matthew transitioned from clinical development into business development, following earlier global clinical operations roles at Novartis and Takeda. He holds a BSc in Chemistry, an MSc in Pharmacology & Biotechnology, and an MBA.

10:00 AM | ANGELS & FAMILY OFFICES

Flexible Capital and Long-Term Support for Early-Stage Innovators

Angels and family offices play a vital role in the life science and healthcare funding landscape, often providing the first capital that enables an entrepreneur to advance their vision. With greater flexibility and a longer-term investment horizon than traditional venture firms, these investors can offer unique advantages to early-stage companies.

This panel brings together active angels and family office investors to discuss how they evaluate opportunities, what differentiates their approach to supporting founders, and how they think about portfolio diversification in healthcare. Panelists will explore investment motivations, decision-making processes, and ways they add value beyond capital. Hear directly from investors whose patient, flexible funding strategies can help lay the foundation for breakthrough healthcare innovations.

Mohammad Khobreh, Co-Founder and Managing Partner, NG Bio (Moderator)



Mohammad is the co-founder of NG Bio, where he leads the fund's strategic direction and works closely with limited partners and co-investors to maximise portfolio value. He excels at building partnerships with major pharmaceutical companies and guiding startups through financing, growth planning, and exit strategy. Previously, Mohammad built and led a family office's life sciences investment platform, delivering over 3.5x returns in six years. His experience spans deal sourcing, due diligence, portfolio strategy, and board leadership across multiple biotech companies.

Naz Bashir, Director, Evolutia Venture Partners



Dr Naz Bashir has over two decades of experience in investment, venture building, within the Health, Biotech, Diagnostics, and Therapeutic development sectors. He directs a family office Evolutia Venture Partners with partners in the Middle East. The firm invests up to GBP £5M in early-stage biotech, medtech, therapeutics and deeptech companies and upto £20M during the lifecycle. The firm takes an active role in its portfolio and invests on a global basis. Naz has PhD Chemistry and an MBA.

Rosie Barnett, Principal, Delin Ventures




Rosie Barnett is a Principal at Delin Ventures since October 2022 and currently serves on the boards of multiple organizations, including Swarm Oncology, uMed, and Ori Biotech. With a longstanding role as a Physician at NHS since 2016, Rosie also contributed to McKinsey & Company as a Next Generation Women Leader from April to December 2022. Previously held positions include Head of Strategy & Business Development at a stealth mode diagnostics start-up, and Strategy & Business Development Manager at Babylon Health. Early career experiences include roles at MedShr as Clinical Manager and Clinical Fellow. Rosie holds a BMBS in Medicine and a Bachelor of Medical Sciences (BMedSci Hons) from the University of Nottingham and completed high school at Bristol Grammar School.

Laurent Pacheco, Managing Partner, International Family Offices Alliance for Health (IFOAH)



Dr. Laurent Pacheco is the managing partner of the International Family Office Alliance for Health (IFOAH). He is a physician (MD) and health economist with a PhD and an MBA. He is also the chairman of the London VC Network, an angel and VC investor with Solas Bioventures. Laurent started his career at PwC, eventually became head of life sciences at BearingPoint. He worked in Paris, New-York and London before joining the industry as managing director for medical affairs and market access at Syneos Health. In parallel of his investment roles Laurent has remained an academic at King's College London where he supervises research in health economics. Laurent is a global speaker and contributes to policy making. In 2025 Dr. Pacheco was elected as a Fellow of the Royal Faculty of Pharmaceutical Medicine in the UK; he is an alumni of La Sorbonne-Paris, Oxford University and King's College London.

Yvette Lu, Venture Partner, BE Health Ventures



Yvette is passionate about advancing healthcare and brings experience shaping executive decisions, driving business strategy, and enabling commercialisation across therapeutics and med-tech. She excels at creative problem-solving with diverse teams and has delivered measurable growth in both startups and Fortune 500 companies. Yvette holds a DPhil in Oncology from Oxford, an MSc in Immunology from Imperial, and executive training in AI design and financial modelling. A devoted art and history enthusiast, she is also an active swimmer, hiker, and former collegiate gymnastics gold medallist.

11:00 AM | MEDICAL DEVICES & DIAGNOSTICS

Forward Looking Trends in MedTech Innovations

Medical devices and diagnostics remain cornerstones of healthcare innovation, driving earlier detection, more accurate diagnosis, and better patient management. From Class I to Class III devices and from point-of-care tests to complex diagnostics, companies are pushing boundaries in usability, cost-effectiveness, and clinical impact.

This 50-minute panel convenes investors and strategics with deep expertise in devices and diagnostics. Panelists will discuss what they look for in new technologies, how regulatory and reimbursement pathways influence their investment theses, and the emerging trends shaping the field. Join the conversation to understand where capital is flowing and how innovators can position their products to improve patient outcomes and meet unmet clinical needs.

Jeff Stinson, Director, HealthTech Arkansas (Moderator)



Jeff founded and leads HealthTech Arkansas ("HTA"), an organization that drives innovation for the state's largest hospitals, health systems and physician practices through both accelerator programs and internal innovation programming. HTA's flagship programs include the HeartX accelerator and the Northwest Arkansas Biodesign Sprints program. Additionally, Jeff founded and has led six early-stage investment funds, including Fund for Arkansas' Future ("FAF"), which was the state's first angel investment group. Across two funds and with 100 members across the State of Arkansas, FAF invested \$10.6 million in 36 Arkansas tech startups. Jeff served as director of UALR TechLaunch - the technology transfer office at the University of Arkansas at Little Rock - from 2012 through 2015, where he implemented a number of programs to increase invention disclosures and promote cross-campus collaboration in technology development. In 2015, Jeff founded the Delta I-Fund, a private version of the I-Corps program. After obtaining his MBA, with honors, from the Owen School of Management at Vanderbilt University, he moved to Arkansas in 1999 and has worked extensively in the private equity markets and in the health innovation ecosystem.

Sophie Humbert, Senior Partner, M2Care



Sophie Humbert is a Senior MedTech Executive with a strong track record of bringing innovation from concept to market with proven leadership, team building, and strategic skills. She has successfully built and led several start-ups in Europe and US, resulting in strategic acquisition. As Senior Partner at M2Care, a Venture Studio investing in healthcare innovations, Sophie leverages her operational expertise to accelerate start-up growth. Through M2Care's hands-on model, she works closely with founders to refine strategies, strengthen teams, and drive operational excellence, turning visionary ideas into high-impact healthcare ventures.

Robert Feldman, Head, CS Ventures



Robert combines over 30 years of medical, academic, and business expertise in the biotechnology and medical technology industries. A qualified medical practitioner, he studied at three of the world's top ten universities, earning his medical degree in London and a PhD in the Netherlands. His career includes roles at Harvard Medical School and Imperial College London, as well as founding multiple biotechnology companies in the UK. Robert has led European operations for Paramount Biosciences, LLC, and served as Entrepreneur in Residence at Imperial Innovations, London. In 2010, he moved to New Zealand to become Executive Director at Pacific Channel, a leading venture investment firm. He possesses a breadth of medical and research expertise encompassing therapeutics, devices, diagnostics, and functional health preparations, with a proven ability to commercialize early-stage technologies. Robert's global experience includes successful business development and licensing deals across Europe, the USA, Australia, Russia, South Korea, and New Zealand. With a nuanced understanding of the challenges in bringing innovations to market, he excels at transforming early-stage technologies into impactful solutions that advance human health.

1:00 PM | DIGITAL HEALTH & AI

Harnessing Technology to Transform the Patient Journey

Digital health and artificial intelligence are reshaping the healthcare ecosystem, offering solutions that enhance patient engagement, reduce costs, and improve clinical decision-making. Investors are increasingly drawn to platforms that leverage data, predictive analytics, and scalable delivery models to create impact at population scale.

This panel brings together leading investors and experts in digital health and AI to discuss what excites them in this rapidly evolving space. Topics will include data privacy, integration into existing health systems, and pathways to commercialization. Panelists will share how they evaluate business models, manage regulatory considerations, and identify companies capable of delivering both strong returns and meaningful improvements in care delivery.

Garth Smith, Vice President, Business Development & Partnerships, Ontario Brain Institute (Moderator)



Dr. Smith is the VP, BD and Partnerships for the Ontario Brain Institute. His mandate is to manage the OBI's commercialization and investment efforts, along with driving impactful partnerships with stakeholders and key collaborators. Currently, he is activating a wholly owned, for-profit spinoff of the OBI to scale up its investment capabilities and partnership activities, globally. Previously, his career has included leading two (2) CNS start-ups, towards their first-in-human clinical trials which culminated in acquisitions by multinational corporations, as a proprietor of a product development/regulatory consultancy and as a tech transfer officer at Canada's largest research institute. His academic career in neurosciences began with a BSc at the University of Toronto, an MSc at the University of British Columbia, a PhD at the University of Cambridge where he was designated as a Cambridge Commonwealth Trust Scholar and was completed as a post-doc fellow at the University Health Network in Toronto.

Alpesh Doshi, Managing Partner, Redcliffe Capital




A founding partner of Redcliffe Capital, the firm specializes in investing in and building companies that help enterprises and entrepreneurs leverage innovation in technology such as digital transformation, , Data and Artificial Intelligence. Redcliffe's investment thesis focuses on the AI First Everything approach. A fundamental change in businesses will emerge in the coming years and provide significant opportunities in every industry. Alpesh's career started over 25 years ago after graduating in Computer Science and he now works helping enterprises innovate and implement new technology and business models. He believes that technology tied with business change can transform an enterprise or an industry. He works in the financial services, insurance, energy, telecoms and media and entertainment sectors.

Jaspreet Grewal, CEO & Co-Founder, AxialBridge



Jaspreet Grewal is an accomplished Clinician-Researcher turned Venture Partner, Strategic Consultant and Board Director with nearly 20 years of experience in the healthcare and life sciences industries. She is a published researcher with experience in over a dozen therapeutic areas, and exposure to the largest healthcare investment markets in the world whilst working in clinical medicine, R&D (for pharmaceutical and medical device companies) and in an advisory capacity for biotech companies. Jaspreet holds a Master's in Clinical Vision Sciences from Georgetown University, an Executive Certificate in Public Health from Harvard University and an Executive MBA from the London School of Economics and Political Science. She has successfully merged her expertise and passion for innovation, research and finance to become a dynamic leader not only nationally but internationally. She's passionate about supporting her diverse international clientele in the areas of clinical research, strategic consulting and access to capital and deal flow.



Soyoung Park, General Partner, 1004 Venture Partners

Soyoung is a visionary leader who aims to keep people healthy through transformative longevity technologies and healthcare infrastructures. With 15+ years of extensive experience in entrepreneurship and investment, Soyoung has invested in 20+ emerging life sciences companies and contributed to the exits of 3 companies through acquisitions with 3-5x cash-on-cash return multiples. Soyoung holds a Master of Business Administration from the Fuqua School of Business at Duke University.

2:00 PM | UK / EUROPE ECOSYSTEM

Global Opportunities in a Dynamic Innovation Landscape

Europe, and the UK in particular, continues to be a hub of healthcare and life science innovation. From strong academic research institutions to growing clusters of biotech and medtech startups, the region is attracting global capital and forging cross-border partnerships. For investors and entrepreneurs, understanding this ecosystem is critical to tapping into its unique opportunities.

In this 50-minute panel, investors and ecosystem leaders from the UK and Europe will share perspectives on fundraising, regulatory environments, and collaboration opportunities. Learn how European startups are scaling internationally, how regional policies shape innovation, and where global investors are finding compelling opportunities across the continent.

Oliver Sims, Investment Manager, Octopus Ventures (Moderator)



Oliver leads Octopus Ventures biotech investment strategy in early-stage companies across Drug Discovery, Research Tools, Diagnostics, and Engineering Biology. His academic background is in Biomedical Science and Biochemistry. He worked in Business and Corporate development in biologics drug discovery, gene editing tools, breath diagnostics. Oliver also founded his own start up for digital prediction and mitigation tools for bipolar patients. He moved into investing with Meltwind, which is the family office of Jonathan Milner who is one of the UK's most successful biotech entrepreneurs and is now a Principal at Octopus Ventures. He is a UK Government advisor for Engineering Biology and a Fellow of Life Science and Deeptech Venture Capital with the Royal Academy of Engineering and Imperial College.

Arvind Shandilya, Investor, Calculus Capital



Arvind joined Calculus in 2022. Sitting within the Investment team, he works on all aspects on the investment process - from sourcing and investing in new investment opportunities to engaging with broader ecosystem of founders/advisors. Over the last decade, he has held various strategic roles across operations & strategy, digital transformation, and business innovation in Fortune 500 corporates (Reliance and Fluor). Through these years, he has built a passion for technology and an understanding of range of sectors making him a great fit with Calculus as a generalist investor. Arvind holds a Bachelor of Technology from Indian Institute of Technology (BHU), and an MBA from University of Cambridge Judge Business School where he focused on Finance and Entrepreneurship.

Jerry Wu, Managing Director, Long River Investment (LRI)



Jerry is the Managing Director at LongRiver Investments, a global venture capital fund that closed its debut USD \$385M fund in July 2024 with leading European and Asian institutional LPs, focusing on life sciences, healthcare, and deep tech. Previously, he served as Head of Investment at TusPark Holdings UK, overseeing £220M+ deployed in UK science and technology since 2018 across venture capital, cross-border M&A, and infrastructure. With 25+ years of experience as a principal scientist and investor, Jerry combines deep R&D expertise with a passion for innovation, collaboration, and leadership development. His career includes roles at AstraZeneca/MedImmune, EMBL-EBI, the Wellcome Sanger Institute, CIMR, BBSRC, and the UK Parliamentary Office of Science and Technology. He holds a PhD in Computer Science, is an Associate at Cambridge Judge Business School, a Senior Advisor at Schwarzman College, and a Lean Sigma Master Black Belt.

Chloe Zhang, Investor Relationships Manager, CPI Enterprises



Chloe is the Investor Relationships Manager of CPI Enterprises, based in London to expand the deep tech and healthcare investor community, and to engage with academia and SMEs to explore potential investment and partnership opportunities. Besides full-time job at CPIE, she's also the UK Chapter at ImpactVC, the advisor to a Chinese family office and a mentor to some accelerators. Prior to joining CPI, Chloe has 9 years significant experience of the early-stage investment ecosystem. She was partner at China's first and largest entrepreneurship educational platform and incubator before co-founding a US-China-based micro-VC and accelerator, which she later exited successfully. She then launched the UK entity of a family office and CVC, G5 Capital, before joining CPI in 2022. Chloe started her career in media and consulting. She holds an MBA from Imperial College Business School and a MSc in Financial Journalism from City University London.

3:00 PM | EARLY STAGE THERAPEUTICS

Accelerating Breakthrough Therapies in Pre-Clinical and Early Clinical Stages

The earliest stages of therapeutic development demand vision, conviction, and capital. Investors in early-stage therapeutics face unique challenges: high scientific risk, long timelines, and the need to carefully validate mechanisms of action before reaching clinical milestones. Yet, it is precisely at this stage where transformative medicines are born.

This 50-minute panel convenes investors and fund managers focused on early-stage drug development to explore how they evaluate novel modalities, indications, and platforms. Panelists will share perspectives on building strong scientific foundations, partnering with academic institutions, navigating regulatory pathways, and supporting teams as they transition from preclinical to clinical development. Attendees will gain insights into what it takes to secure investment, structure early deals, and build the right syndicates to carry a therapeutic program toward clinical proof-of-concept.

Mara Sprouse, Director of Commercial Operations, Mosaic Biosciences (Moderator)



Maran Sprouse is Director of Commercial Operations at Mosaic Biosciences, where she leads strategic initiatives to streamline processes, optimize systems, and enable cross-functional teams to deliver with speed and efficiency. With over 12 years of experience spanning research, operations, and business leadership, she has built a career at the intersection of science and execution. Beginning in immunology research at Baylor College of Medicine, Mara now partners with scientific and commercial leaders to design scalable solutions supporting Mosaic's growth in therapeutic development, antibody discovery, and protein engineering—bridging scientific innovation with commercial execution.

Richard Kaschula, Venture Builder, NG Bio




Richard brings over a decade of scientific research experience to NG Bio, where he sources and evaluates high-impact opportunities with strong scientific and commercial potential. Formerly a LifeArc Technology Transfer Fellow, he combines expertise in developmental genetics, genomics, and fundamental biology with a growing understanding of biopharma finance. He holds a PhD and postdoctoral experience from The Francis Crick Institute, plus a master's in Finance. A systems thinker and collaborative problem-solver, Richard excels at assessing innovation while keeping sight of the broader strategic landscape.

Maria Shutova, Senior Investment Manager, Cell and Gene Therapy Catapult



Maria Shutova, based in United Kingdom, is currently a Senior Commercialisation of Research and Investment Manager at Cell and Gene Therapy Catapult. Maria Shutova brings experience from previous roles at Cell and Gene Therapy Catapult, Freelance and 4BIO Capital. Maria Shutova holds a 2008 - 2012 Doctor of Philosophy - PhD in Molecular Genetics @ Vavilov Institute of General Genetics, Russian Academy of Sciences. Maria Shutova has 1 emails on RocketReach.

Emilie Syed, Senior Investment Manager, Zinc VC



Emilie has nearly a decade of experience in building and investing in university spinouts, as part of the Investment Committee at Parkwalk Advisors and previously at Oxford University Innovation, where she worked both in Investments and leading the Startup Incubator, managing over 80 ventures from inception to exit. She moved into technology transfer after 14 years as a research scientist, directing pioneering experiments in systems neuroscience in Oxford, Bordeaux and Hamburg. Emilie holds a PhD in Neuroscience from the University of Hamburg and an MBA from Warwick Business School, specialising in Strategy and Finance.

4:00 PM | SEED FUNDS

Catalyzing the Earliest Stages of Healthcare Innovation

Seed funds provide the critical early-stage capital that helps transform bold scientific ideas into viable healthcare ventures. By investing at the riskiest point in a company's journey, seed funds fuel innovation that may not yet attract larger institutional capital, but has the potential to create transformative impact.


This 50-minute panel brings together managers of seed-stage funds to discuss how they identify promising founders and technologies, structure early deals, and support portfolio companies through the difficult first stages of growth. Panelists will also share perspectives on syndication strategies, bridging to Series A, and how they add value beyond financing. Learn what it takes to secure early backing and build momentum from the very start.

Nick Naclerio, Founding Partner, Illumina Ventures (Moderator)



Nick is the Founding Partner of Illumina Ventures. His passion is building companies at the intersection of technology and human health. Prior to joining the fund, he served as SVP, Corporate & Venture Development for Illumina Inc., where he was responsible for strategic planning, business development, licensing, venture investing and acquisitions. In six years, Nick and his team completed ten acquisitions, more than a dozen venture investments, and a multitude of other transactions including the formation of Helix and GRAIL and the creation of a global NIPT patent pool. Nick also served as the founding General Manager of Illumina's Enterprise Informatics Business Unit. Before joining Illumina Inc., Nick co-founded and was the Executive Chairman of the diagnostics company Quanterix. Previously he was Executive Chairman of True Materials and CEO of ParAllele BioScience, life science tools firms that were both acquired by Affymetrix. Nick got his start in venture investing at Motorola where he led the life science investment team and served on the boards of the SNP Consortium, Genometrix, Clinical Microsensors, and Orchid Bioscience. He founded and led Motorola Life Sciences, an early microarray company that was acquired by GE. He also held leadership positions at DARPA and served on the board of SEMATCH. Nick received a B.S. in Engineering from Duke University, was a Winston Churchill Scholar at Cambridge University, and earned a Ph.D. in Electrical Engineering from the University of Maryland.

Lina Gaydarova, Investment Manager, Novaterra




Lina Gaydarova is an early stage life sciences investor at Novaterra, Italy's first international pre-seed & seed impact fund. Lina is based in Milan, and actively invests across biopharma in CNS & oncology as well as wet lab diagnostics in EU/US geographies. Prior to Novaterra, Lina was an investor at Bessemer Venture Partners in San Francisco focused on enterprise and healthcare while executing early stage biopharma oncology investments as an LP in an angel fund. Lina's early career was a mix of investment banking & growth equity across infrastructure technology, which she leveraged as a launchpad to break into early stage life sciences investing.

Hassan Mahmudul, Investment Manager, Future Planet Capital



Matthew has over twenty years of experience as a venture investor, focusing on highly disruptive healthcare, medtech and life science opportunities. After a brief research career, he moved into venture capital, making seed investments with an Oxford Technology Management, before co-founding Longwall Venture Partners. Longwall has raised three funds over the last fifteen years, and invests in early stage, UK-based science, engineering and healthcare businesses. Matthew has a D.Phil (Biochemistry) from Oxford.

Prashant Shah, Partner, O2h Ventures



Prashant is the CEO of o2h discovery, General Partner of the o2h venture seed funds, and co-founder/co-CEO of the o2h group, whose mission is to seed new ideas in life sciences and technology through seed investment, incubation, and R&D services. He led the award-winning Mill SciTech Park redevelopment in Cambridge, where the group is headquartered, and has built an international footprint across the UK, USA, and India. A serial entrepreneur from the dot-com era, he co-founded a drug discovery company acquired by a major public firm and now actively invests in nearly 50 seed-stage companies. He has extensive experience building teams, companies, and lab/office infrastructure globally, and holds multiple board and chair roles across techbio, biotech, and regional innovation organizations. Prashant began his career in Accenture's strategy group and is also an author. He holds a BEng, an MSc (Human Genome Project robotics, Sanger Centre), and an MPhil in Management from Cambridge University.

9:00 AM - 4:50 PM | INNOVATOR'S PITCH CHALLENGE

9:00 - 9:50 AM

SESSION #1

THERAPEUTICS



Easel #5



Easel #19



Easel #8



Easel #20

10:00 - 10:50 AM

SESSION #2

DIAGNOSTICS TOOLS & PLATFORMS



Easel #7



Easel #17



Easel #14



Easel #21

11:00 - 11:50 AM

SESSION #3

THERAPEUTICS



Easel #18



Easel #1



Easel #4



Easel #11

1:00 - 1:50 PM

SESSION #4

THERAPEUTICS & MEDICAL DEVICES



Easel #2



Easel #3



Easel #26



Easel #6

2:00 - 2:50 PM

SESSION #5

THERAPEUTICS



Easel #12



Easel #25



Easel #15



Easel #9

3:00 - 3:50 PM

SESSION #6

MEDICAL DEVICES



Easel #22



Easel #23



Easel #16

4:00 - 4:50 PM

SESSION #7

R&D AND ENABLING TECHNOLOGIES



Easel #13



Easel #10



Easel #24

9:00 AM | SESSION 1 - THERAPEUTICS



4C Biomed Limited, based in London, UK with R&D in Netanya, Israel, is an IND-ready immuno-oncology company. Founded as a spin-off from Sheba Hospital, it uses a sensitive screening platform to identify therapeutic targets from ~8,500 genes. Clinical trials published at ASCO 2024 highlight the potential of the HVEM-BTLA axis. Our lead antibody, anti-4CB1, a first-in-class monoclonal antibody, targets HVEM and blocks both the HVEM-BTLA and HVEM-CD160 interactions, positioning it as a superior competitor to BTLA-targeting therapies. Anti-4CB1 shows promising results, including in-vivo studies with anti-PD1 and enhanced cytotoxicity as a monotherapy in twice as many ex-vivo patient samples as the gold standard anti-PD1, across various solid cancers. Anti-4CB1 is well tolerated, as shown in GLP toxicity studies in cynomolgus monkeys, and is ready for clinical trials. We seek a licensing deal or \$20m Series A funding, with existing investors participating.



HEPHAISTOS is a preclinical stage Biotech designing and developing new engineered innate activators to tackle the biggest challenge in oncology: offering an option to the 70% patients that do not respond to current immunotherapies. HEPHA440 is HEPHAISTOS' first candidate. Its efficacy has been demonstrated against primary tumors and metastases, both as single agent and in combination with other immunotherapies. HEPHA-440 has been granted an orphan drug designation for the treatment of osteosarcoma and is on track to enter clinical development by 2027 in solid tumors. Multi-awarded and multi-granted, HEPHAISTOS is the result of the meeting of two class "A" scientists: Dr. Martine Caroff, a pioneer in molecular signaling biology and engineering, and Pr. Charles Dumontet, a leader in immuno-oncology and hematology. The company is based in Paris, Lyon, and Liège



ImmunoKey is a UK-based biotechnology company developing next-generation CAR T-cell therapies to treat solid tumours, an area where current cell therapies have failed. Our proprietary CARKey™ platform uses tri-specific antigen targeting to ensure maximal coverage of heterogeneous tumour cell populations, combined with a logic gated safety switch to mitigate off-tumour toxicity. This is complemented by AmpliT™ and ReviT™ technologies to enhance T-cell persistence and overcome immunosuppressive microenvironments. Our modular system is broadly adaptable across solid tumour types. We are initially focused on relapsed ovarian cancer, where >80% of patients relapse after first-line therapy. Founded by the team behind Immetacyte (acquired by Instil Bio), our leadership brings extensive experience in cell therapy R&D, GMP manufacturing, regulatory strategy, and company exits. We are currently raising a £3.2M seed round (EIS approved) to deliver IND-enabling data by 2026 and position us to achieve clinical proof of concept data and exit opportunities by 2030.



Oncovita is a pre-IND/CTA-stage biotech company based in Paris and a spin-off from the Institut Pasteur. We are developing MVdeltaC, a next-generation oncolytic immunotherapy lead product based on genetically modified measles vaccine strains. This approach offers a strong safety profile and targeted immune-mediated tumor destruction. MVdeltaC, is expected to enter a First-in-Human Phase I trial in 2026, both as monotherapy and in combination with an immune checkpoint inhibitor. A Phase IIa study will follow, targeting Pleural Mesothelioma (for which we received in June the Orphan Drug Designation from the FDA) and Triple-Negative Breast Cancer. We have generated robust preclinical data, a promising case report, and benefit from scientific backing from the Institut Pasteur—all of which reinforce the potential of our platform and its favorable risk profile.

10:00 AM | SESSION 2 - DIAGNOSTICS TOOLS & PLATFORMS



BIOCAPTIVA is developing innovative sample preparation technologies that enable high-yield, high-quality extraction of cell-free DNA (cfDNA) directly from whole blood. Its lead technology, msX, is a proprietary polymer coating platform that can be applied to virtually any substrate, including magnetic beads, to enable efficient cfDNA isolation without the need for plasma separation. The first product, msX-coated magnetic beads, allows extraction from any sample volume, overcoming the input size limitations of current technologies and streamlining laboratory workflows. By maximizing cfDNA recovery and purity, msX enhances the performance of downstream molecular analyses used in cancer diagnostics and minimal residual disease monitoring. The platform is fully compatible with existing automated systems and cfDNA assays, offering scalable and reliable integration into routine testing. BIOCAPTIVA's mission is to remove key barriers in the liquid biopsy workflow, enabling earlier, more accurate, and accessible cfDNA-based precision medicine.



BreathPredict is revolutionising respiratory care with Exhale-Dx®, the first AI-powered breath test that predicts asthma attacks up to three days in advance with 93% diagnostic accuracy. The technology uses a patented breath biomarker detection system and deep learning framework to enable proactive, personalised asthma management – reducing attacks by up to 55% in pilot studies. Backed by £670k in funding from Bethnal Green Ventures and Innovate UK, BreathPredict has secured two LOIs with CRO and pharma partners and is progressing toward UKCA certification in 2025. With partnerships including Asthma + Lung UK, the American Lung Association, and the NIHR, the company is positioned for rapid commercial scale. Targeting a £20B global asthma diagnostics and monitoring market, BreathPredict's model combines device sales, SaaS subscriptions, and data licensing, driving high-margin recurring revenue and a scalable path to global adoption.



STRATISAL is a pre-spinout from the Francis Crick Institute developing the first real-time, functional DNA-repair platform to transform how cancer treatment decisions are made. While oncology today depends on static genomic and protein biomarkers that often fail to reflect how tumours actually behave, STRATISAL's platform directly measures how tumour cells repair their DNA – effectively putting them through a controlled “stress test.” Using proprietary plasmid constructs, buffers, and multiplexed repair-pathway readouts, the assay reveals each tumour's true DNA Damage Response (DDR) profile. In the near term, STRATISAL provides pharma and CRO partners with a powerful research tool to validate DDR inhibitors and de-risk clinical trials; in the long term, the same technology will enable functional companion diagnostics that guide therapy selection. STRATISAL's vision is for every cancer patient to be diagnosed and treated based on the real-time functional biology of their tumour, making precision medicine a measurable reality.



Hi, I'm Javier from Ysium Medical, a MedTech company based in Navarra, Spain. We're building a medical learning platform for healthcare professionals and patients, combining advanced physical simulators with digital and mixed-reality experiences to make clinical training more realistic, accessible, and data-driven. Every year, millions of doctors and nurses graduate without enough hands-on practice – leading to medical errors and missed early detections. Over 20% of blood draws cause hematomas due to poor technique, and 16.6 million women in Spain are at risk of breast cancer, where early detection is critical. The medical simulation market here alone exceeds €500M. Our simulators provide ultra-realistic tactile training, connected to a digital platform for self-learning, performance tracking, and even patient training at home. We've already launched our first products, validated by leading universities, achieving a 60% conversion rate and a community of 2,000 B2C prospects ahead of our e-commerce launch this November.

11:00 AM | SESSION 3 - THERAPEUTICS



Allogeneica is an innovative biotechnology company developing next-generation cell therapies to treat solid tumors. Our approach is based on allogeneic T cells engineered with T Cell Receptors (TCR), leveraging the unique properties of immature pre-T cells to create universal, safe, and scalable “off-the-shelf” treatments. Within two years, Allogeneica will advance its first product into clinical trials, supported by strategic collaborations and licensing agreements with major pharmaceutical partners. Preclinical studies have shown complete tumor elimination across several tumor models, demonstrating strong persistence and absence of rejection. Unlike most allogeneic approaches, our cells undergo only a single genetic modification, ensuring superior safety for patients and simplifying manufacturing. By combining cutting-edge TCR technology with a unique pre-T cell platform, Allogeneica aims to make cell therapy accessible to all and transform the treatment landscape for patients with solid tumors worldwide.



BDUK-Tx developed a breakthrough liver cancer therapy, EmboPore, combining existing drugs into a novel therapeutic product. The \$11Bn liver cancer market has no effective treatment and very low survival rate. The prestigious ERC research grantee, EmboPore, was developed by Prof. Ofra Benny, The Hebrew University. Our leadership brings strong multidisciplinary, product-oriented approach and is working to reach an acquisition or license deal after Phase-1 readout.



Diamante is a biotech company developing targeted therapies for autoimmune diseases, with a focus on rheumatoid arthritis. Leveraging a patented technology platform, Diamante aims to improve patient outcomes by addressing the underlying mechanisms of disease with precision and safety. The company's lead candidate has shown promising preclinical results and is advancing toward clinical development. Diamante is supported by European innovation grants, including the prestigious EIC Accelerator, and collaborates with academic and clinical partners across Europe. With a strong scientific foundation and a clear regulatory strategy, Diamante is positioned to deliver first-in-class solutions in a market with high unmet medical need. The company is currently seeking strategic partners and investors to accelerate its development pipeline and expand its impact.



OncoLize (Leiden, NL) develops injectable drug depots for localized, intra-tumoral drug delivery using generic and novel drugs: 125x higher concentration at target, 100x smaller total dose versus SoC pto 1000x lower drug levels outside of the tumor... Improved Survival, Less/no side effects, Affordable. Expert management team with world-class KOLs in Pancreatic cancer, backed by ambitious cornerstone investors. Patents granted in USA-EU-China-Japan, great FTO-analysis. Established PDAC animal models demonstrate spectacular results: 100% survival, no side effects, immune activation. Excellent safety/tox profile, easy scale-up, readily applied in existing practises. Raising €3.5 million by Q1-2026 to execute First-in-Patient and 1A/2B trials in 4 centers. the round is 60% subscribed with existing and new investors. Series A of €17 mln by end of 2027 to expand the portfolio to other solid tumor indications based on proven Product Platform. Exit by 2031, EBITDA year 10 ±550 mln, annual ROI 80%

1:00 PM | SESSION 4 - THERAPEUTICS & MEDICAL DEVICES



IMBT is developing natural, sustainable, safe alternatives to antibiotics for farmed animals and humans. These are functional foods in the form of Immune stimulated insect larvae that produce an array of Innate Immune components called Antimicrobial Peptides (AMPs), now called Nature's Antibiotics. These AMPs support the immune system and can address various gut infections that can impact health, welfare and productivity. IMBT holds patents for the technology and is looking for investment and/or licencing opportunities to bring the product to market.



Keyron Medical Technology is developing ForePass®, the first fully reversible, incision-free alternative to bariatric surgery for severe obesity and metabolic disease. Placed and removed endoscopically in under 30 minutes, it delivers substantially faster and greater weight loss than drugs while reversing diabetes, NASH, and liver fibrosis. Over 50 million adults in the US and EU with BMI ≥ 35 and diabetes lack effective, non-surgical options; GLP-1 drugs fail long term and surgery remains too invasive. In large-animal studies, ForePass® achieved 8x greater weight loss and 2x greater diabetes effects vs Semaglutide (Ozempic). Led by Dr Giorgio Castagneto Gissey, with the former FDA Medical Device Director and Boston Scientific veterans, Keyron has raised \$3.4M to date and is now raising \$7.5M (\$5.5M committed) to complete GLP studies, obtain FDA IDE approval, and complete its First-In-Human trial.



Nano Painkiller is developing a targeted, next-generation approach to chronic pain relief, addressing a condition that affects roughly 20% of adults in Western populations and represents a significant global economic burden. Today's chronic pain treatments often require lifelong medication, with many options carrying risks of dependence—contributing to challenges such as the U.S. opioid crisis. Nano Painkiller's technology uses a proprietary nanomaterial designed to selectively ablate only the sensory nerves responsible for pain while preserving motor function and surrounding healthy sensory neurons. By focusing ablation precisely at the dorsal root ganglion (DRG), the platform can eliminate the specific pain-transmitting fibers while maintaining 99% of the ganglion intact, and can be applied across multiple DRGs when needed. The procedure involves delivering nanomaterial to the affected organ, mapping the relevant DRG, and performing selective, localized nerve ablation to provide durable, non-opioid pain relief.



Oxolife is a specialist clinical-stage biotech company focused and committed to improving women's health and female fertility. Its lead program, OXO-001, is designed to act directly on the endometrium to enhance embryo implantation, additionally improves metabolic health, restores ovulation and reduces pregnancy loss increasing live birth rates, including specifically for women with polycystic ovary syndrome (PCOS).

2:00 PM | SESSION 5 - THERAPEUTICS

Drug4Sight

Drug4Sight is an innovative spin-off in formation from the Institute for Bioengineering of Catalonia (IBEC), dedicated to restoring vision in degenerative retinal diseases through advanced light-regulated therapeutics. The company has developed a series of light-responsive small molecules that specifically target neuronal proteins located upstream in the retinal circuit. Supported by strong scientific and preclinical foundations, Drug4Sight aims to secure Orphan Drug Designation for Retinitis Pigmentosa in 2026, leveraging the benefits of fast-tracking, market exclusivity, and targeted funding. Building on this foundation, the company intends to extend its medical indications to include Adult Macular Degeneration and other major retinal disorders. Through this strategy, Drug4Sight positions its platform as a versatile, non-invasive and affordable next-generation solution for vision restoration suitable for a wider patient population.



Our lead product, MLB-001, is a first-in-class, combination drug designed to deliver powerful, life-changing pain relief using significantly lower morphine doses. MLB-001 achieves equal or superior analgesic effects compared to conventional morphine, while minimizing common side effects and reducing the development of drug tolerance. Importantly, MLB-001 is specifically engineered to lower the risk of addiction, a critical advancement given the ongoing opioid crisis. MindLab is committed to redefining pain care by introducing safer, more effective treatments that address unmet medical needs and promote better quality of life for patients worldwide.



ONESTX is committed to developing novel solutions for age-related neurodegenerative diseases. Our most advanced therapeutic approach is LON-21, a human-safe, oral anti-aging drug with demonstrated preclinical activity in extending healthy lifespan, as well as potential disease-modifying activity in neurodegenerative diseases in animal models. Our objective is to partner with pharmaceutical and/or venture capital companies to conduct a Phase II clinical trial to confirm efficacy in neurodegeneration.



Sania Therapeutics is expanding gene therapy beyond rare disease to make it viable, safe, and scalable for millions. Today's gene therapies work scientifically, but their model doesn't: high doses, systemic exposure, and high price tags keep them out of reach. Sania's human-first AAV design creates fit-for-purpose vectors that reach the neurons driving disease through simple, localized delivery, avoiding the complexity and risks of systemic or high-dose administration. Paired with an oral activator, this approach enables precise, reversible modulation of neural activity, unlocking safer treatments for prevalent neural circuit disorders such as spasticity, bladder dysfunction, and pain. Built for manufacturability from day one, Sania's low-dose design addresses the cost and production barriers limiting gene therapy today. With validated NHP data and lead program IND-enabling work underway, Sania's first-in-kind therapy aims to make gene therapy a practical medicine for millions.

3:00 PM | SESSION 6 - MEDICAL DEVICES



Dyogel is a stabilisation gel that prevents protein aggregation and enables ambient storage of therapeutic proteins – eliminating cold chain dependence. Developed with the University of Glasgow and partners, Dyogel preserves protein structure against heat and agitation, delivering pure injectable biologics. The technology targets the \$823 bn biologics market, addressing stability challenges across monoclonal antibodies, vaccines, insulin, botulinum toxins, enzymes and GLP-1s. Dyogel offers two key opportunities: Post market reformulation for product lifecycle extension and commodity product stabilisation for low-cost access in LMICs. IP: GB2633392A / WO2025052144 www.dyogel.com
Contact: Dr Wes Randle & Dr Libby Marshall



Interlinked AB is entering a pivotal stage, with commercialisation now firmly underway. Recurring hospital sales, a signed €3M minimum distributor contract, we are positioned to scale a clinically validated MedTech platform across multiple global markets. At the core of our growth is ReLink®, the only breakaway connector that keeps IV and drainage systems closed at all times—reducing catheter dislodgement, improving patient safety, and lowering costs for healthcare providers. With applicability across civilian care, nephrostomy drainage, veterinary health, and defence medicine, ReLink represents a multi-segment, dual-use platform with significant commercial potential. This is a compelling inflection point for engagement: * Clinical validation achieved – including a 73% reduction in IV catheter dislodgement * Regulatory approvals in place – CE MDR Class IIa, FDA Class I, ISO 13485 * Commercial momentum building – hospital uptake, distributor sales, and a growing international pipeline * Scalable pathway Data room, including operational, clinical, regulatory, and sales pipeline is available.



Clyype® is a reusable device with bidirectional filtration of up to 99.8% against particles and aerosols. It has been specifically designed for healthcare professionals and critical environments, such as clean rooms, laboratories, hospitals, or veterinary and livestock facilities. This system provides comprehensive protection for the respiratory tract as well as the ocular and auditory interfaces, acting as a shield for the user, the people they interact with, and the surrounding environment, without the need for additional masks. It combines maximum safety, long-term comfort, and ease of disinfection, while ensuring sustainability through the use of reusable hoods and replaceable filters. Altogether, Clyype® is an efficient, versatile, and environmentally friendly solution for professionals who require advanced protection.

4:00 PM | SESSION 7 - R&D AND ENABLING TECHNOLOGIES



Bright Biotech is a Manchester-based molecular farming company revolutionising protein production. We've developed a proprietary chloroplast-engineering technology that enables plants to produce high-value proteins such as growth factors, replacing traditional microbial and animal-cell systems. Our platform achieves exceptionally high expression levels, typically 2-5 grams of protein per kilogram of leaf tissue, and is inherently scalable since production can simply be expanded by growing more from seed. By avoiding microbial and animal systems, we also eliminate the risk of contamination from endotoxins or animal pathogens. Combining high yield, scalability, and safety, Bright Biotech makes essential growth factors more affordable and accessible for regenerative medicine, cell therapy, and other life science applications.



Lovaltech is a French DeepTech startup that specializes in developing nasal vaccine formulations. They're working on a new generation of protein vaccines administered through the nasal route, designed to induce a broad-spectrum immune response, protecting against infectious diseases like COVID-19. Our technology and unique versatile platform aims to block transmission and provide optimal protection by activating a local immune response in the nasal mucosa, potentially stopping the virus at its entry point. Our unique platform consisting of 3 main pillars: the muco-excipients, our expertise in design and production of smart antigens, and the unique medical device produced by Aptar pharma. Lovaltech's lead candidate vaccine, LVT-001, is currently in phase 1/2 clinical trials for COVID-19, with promising results expected. The company has received significant funding, including a €6.8 million seed financing round, to support the development of our nasal vaccine technology.



myotwin combines advanced cardiac organoids and patented measurement technology to create the first scalable digital twin of the human heart. Our platform provides unique, clinically relevant functional data -including tissue stiffness and excitation-contraction coupling -for early, precise prediction of drug efficacy and safety. Powered by AI, myoAI supports pharma and biotech partners in developing safer, more effective heart medications, reduces animal testing, and accelerates preclinical decision-making.



9:00 AM | ACCELERATING EARLY-STAGE DRUG DISCOVERY HOW CRO PARTNERSHIPS FUEL STARTUPS' PATH TO SUCCESS

Early teams live or die by how well they translate scarce capital into decisive biology. In this 50-minute workshop, Mosaic Biosciences – a therapeutics-focused Partnered Research Organization (PRO) – shares practical playbooks for using external discovery partners to compress timelines, sharpen decision-making, and preserve runway. We'll cover when to bring on a CRO/PRO across funding stages, how to scope work that drives go/no-go inflections, and ways to structure SOWs and budgets for flexibility without losing accountability. Through candid case studies and interactive Q&A, we'll dissect common traps (over-dependence, scope creep, misaligned incentives) and show how the right partnership can raise the scientific bar while lowering operational load for lean teams.

You'll leave with:

- A simple "partner fit" scorecard and questions to pressure-test providers
- Negotiation tips and SOW guardrails that protect IP, timelines, and budget
- A milestone-based budgeting map from pre-seed to Series A
- Practical frameworks for choosing discovery strategies (e.g., in vivo vs. in vitro) based on program risk and speed

Hosted by Mosaic Biosciences – engineers, assay builders, and "drug hunters" dedicated to helping founders reach their next value-inflection faster.

Maran Sprouse, Director of Commercial Operations, Mosaic Biosciences



Maran Sprouse is Director of Commercial Operations at Mosaic Biosciences, where she leads strategic initiatives to streamline processes, optimize systems, and enable cross-functional teams to deliver with speed and efficiency. With over 12 years of experience spanning research, operations, and business leadership, she has built a career at the intersection of science and execution. Beginning in immunology research at Baylor College of Medicine, Mara now partners with scientific and commercial leaders to design scalable solutions supporting Mosaic's growth in therapeutic development, antibody discovery, and protein engineering—bridging scientific innovation with commercial execution.



Comprehensive Biologics Discovery Services to Help *Fuel* Your Startup

Startup Pain Points Require PRO Solutions

Startups can't afford delays, shaky data, or missed milestones. The Mosaic team dives into the science with you, which is why we call ourselves **PRO** or partnered research organization.

Here's the **PRO** difference:



SCAN ME



Who we work with:



Start-up companies looking to accelerate research by adding Mosaic's scientific leadership, tactical resources, or infrastructure.



Discovery-stage biotech seeking a partner to take ideas through lead optimization to support early research programs.



Development-stage biotech looking to add or broaden their research capabilities.

- With larger deal sizes, is the gap between the haves and have nots widening?
- Innovative business models vs investor appetite
- Does founder diversity bring investment opportunity diversity?
- Are capital pools on the move?




Eva Haas, Optimum Strategic Communications (Moderator)

Eva Haas is a Senior Consultant at Optimum Strategic Communications, advising life sciences and healthcare companies on strategic positioning and fundraising, including private rounds, IPOs, reverse mergers and follow-on financings. Since 2017, she has supported over 100 clients across Europe and the US. Eva brings 20 years of global healthcare fund management and company analysis experience, previously at Schroders in London and New York. She holds a PhD in Biochemistry from Bristol University and is fluent in German.




Tim Davis, London Stock Exchange

Tim joined The London Stock Exchange in April 2019 and has responsibility for potential AIM and Main Market IPOs across The Midlands, Wales, East Anglia, Cambridge and Oxford. In addition he has national responsibility for Healthcare. Tim spent the previous 20 years working across a range of industry sectors in UK small and mid-cap advisory and broking roles at Teather & Greenwood, Charles Stanley Securities, Religare Capital Markets and Cantor Fitzgerald Europe.



Janette Thomas, Accentbio Ltd

Janette Thomas, Advisor and mentor at Accentbio Ltd, is an experienced pharmaceutical executive and former CEO of Five Alarm Bio, an anti-aging therapeutics company. She has extensive expertise in drug discovery, start-up operations, strategy, project management, fundraising, manufacturing process development, commercial supply, IP, and regulatory strategy. Janette has worked across multiple therapeutic areas and development stages, including chronic wounds, IBD, orphan drug development, oligonucleotide manufacturing, new formulations, and Named Patient programs.



Soyoung Park, General Partner, 1004 Venture Partners

Soyoung is a visionary leader who aims to keep people healthy through transformative longevity technologies and healthcare infrastructures. With 15+ years of extensive experience in entrepreneurship and investment, Soyoung has invested in 20+ emerging life sciences companies and contributed to the exits of 3 companies through acquisitions with 3-5x cash-on-cash return multiples. Soyoung holds a Master of Business Administration from the Fuqua School of Business at Duke University.



Francesca Crawford, F.E.C. Bio

Francesca Crawford, Founder of F.E.C. Bio, is an accomplished life science leader with a strong track record in building and scaling companies organically and through partnerships and M&A. She founded two companies—ViaNautis Bio (UCL spin-out) and Altacor—raising ~\$50M from VCs, pharma corporate ventures, angels, and charities, and securing major collaborations including a recent agreement with Eli Lilly. With deep translational expertise from discovery to clinic, she is a Non-Executive Director at Medherant and a BIA mentor. Francesca brings strategic vision, board leadership, and broad therapeutic experience across neuroscience, oncology, and ophthalmology.



Kate Rowley, Symmetrist

Kate Rowley, Founder of Symmetrist, has over 28 years of life science experience across public and private healthcare, including 11 years in investment and service as both an executive and non-executive board member. Known for her visionary, energetic, and inclusive leadership style, she has successfully led teams and major commercial initiatives throughout her career. Kate's expertise spans business development, deal structuring, technology commercialisation, marketing, and PR, making her a highly effective leader and strategic advisor in the life sciences sector.



Jennifer Laird, Eli Lilly

Jennifer Laird, Eli Lilly, is a pharma leader with a strong track record in partnering, discovering, and developing innovative medicines. She has deep end-to-end expertise from target identification to launch across multiple therapeutic areas and is passionate about advancing new opportunities that improve patient outcomes. Before joining Lilly in 2012, Dr. Laird held senior roles in Translational Science, Project Management, and Pharmacology at AstraZeneca, as well as positions in academia and Merck, bringing broad scientific and leadership experience to her work.

11:00 AM | FIEDFISHER WORKSHOP ON GOOD TERMS: GETTING TO TERMS WITH TERM SHEETS

This workshop provides a deep dive into term sheets for life sciences transactions, including collaborations, fundraising, IPOs, licensing, M&A, JVs, and SPVs. Attendees will explore typical material terms, the balance of binding vs. non-binding provisions, and strategies for negotiation. Topics include exclusivity, cost coverage, break fees, and managing commercial term changes during negotiations. We'll decode fundraising jargon - like liquidation preferences, anti-dilution mechanisms, and board/shareholder rights—and discuss tools such as SAFEs, CLNs, and ASAs. Learn how to navigate the interplay with financial advisors and banks, ensuring alignment on transaction definitions and processes. Legal advice at this stage is crucial; this session offers insights into market norms and practical negotiation tactics to secure better outcomes.

Janita Good, Partner, fieldfisher



Janita Good is a Partner at Fieldfisher, specializing in transactional law across corporate and intellectual property (IP) deals. Her expertise includes venture investment, cross-border structured M&A, pharma asset divestments, licensing, strategic partnering, R&D collaborations, and drug supply agreements. A passionate advocate for life sciences, Janita holds a D.Phil. in Biochemistry from the University of Oxford. She is a fellow of the Royal Society of Medicine and the Royal Society of Biology, serving on advisory committees of the BIA. Previously head of a UK life sciences group at an international law firm, Janita has advised on notable transactions, including Sensyne Health's AIM IPO, Phynova's €10M funding by DSM Venturing, and Acano's \$700M acquisition by Cisco.



12:00 PM | LSN BD ASSIST: YOUR GLOBAL MATCHING AND PARTNERING ENGINE

Fundraising in life sciences is a numbers game. Most programs stop at pitch training, but winning capital takes a 9 to 18 month global campaign with disciplined outreach and relentless follow up. LSN BD Assist runs that campaign for you. Built on four pillars – matching, messaging, meetings, and follow up – we connect you with the right partners by stage, product, and strategic fit while filtering out mismatches. From a curated database of 7,000 investors and licensing partners, we build a 600 to 800 target list, integrate it in Salesforce, update it daily, and drive the outbound so you can focus on science. More than 400 startups have used BD Assist to raise over 5.4 billion dollars.

Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Dennis Ford is an entrepreneur, author, and frontier technologist with deep expertise in sales, marketing, and business development. Dennis has spent a decade in the early-stage life science arena creating a partnering platform that matches next-generation drugs, devices, diagnostics, and digital health products with investor and licensing partners. Dennis has developed an active network of global investors ranging from Family Offices, Private Equity, Venture Capital, Foundations, and Endowments to large Corporate and Pharmaceutical firms interested in high-growth early-stage technologies. Dennis has also pioneered a unique global partnering event called the Redefining Early-Stage Investments Conference Series that matches investors and licensing partners with startup firms based on stage of development and product.

Dennis is the author of *The Peddler's Prerogative* and *The Fund Manager's Marketing Manifesto*, two well-received sales and marketing books. His latest book is *The Life Science Executive's Fundraising Manifesto* which he turned into a two-week immersion class for scientist-entrepreneurs and fundraising CEO which is now offered to help launch and fund startups into the global life science arena.

Karen Deyo, VP of Product, Israel BD, Life Science Nation

Karen Deyo is the VP of Product at Life Science Nation, responsible for new product development and LSN's educational content. In addition to her role as VP of Product, she is actively involved in Israel BD, utilizing her professional and personal connections to connect LSN to the Israeli life sciences startup community. She started out at LSN as part of the investor research team, speaking to investors and learning their investment mandates. Karen utilizes her experience speaking with investors as well as her scientific background to help startups translate their science and prepare for their global partnering campaigns. Karen has a Masters of Engineering in Biomedical Engineering as well as a Certificate in Graduate Business Study from Worcester Polytechnic Institute and a Bachelor of Science degree in Engineering with a concentration in Bioengineering from Olin College of Engineering.

1:00 PM | TALES FROM THE ROAD

BIOTECH AND MEDTECH INNOVATORS ON THEIR FUNDRAISING JOURNEY

The industry has quickly adapted to a “new normal” – entrepreneurs and investors meet virtually over digital platforms to discuss potential investment opportunities, and it is not uncommon to see entrepreneurs raise capital from investors they have never met before in person. That said, there is no doubt that the fundraising journey continues to be challenging for many. In this panel, you will be able to hear fellow entrepreneurs share their experiences, from successes to challenges. This panel will discuss the following topics and more:

- What are some of the greatest challenges entrepreneurs have faced, especially during the pandemic, and how were they overcome?
- How did entrepreneurs identify investors that fit their technology?
- What are some misconceptions entrepreneurs had about the early-stage investment landscape?

Furthermore, entrepreneurs will share unique tips and insights they have gained from their fundraising experiences, and how others can work their way towards a more successful campaign.

Greg Mannix, VP of International Business Development, Life Science Nation (Moderator)



Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master's degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in large medical device corporations and small start-ups alike, giving Greg a well-rounded international experience in the healthcare field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg relocated to Boston 6 years ago to set up the US affiliate for an early-stage Med-tech company from Spain and he immediately took to the vibrant startup community there. Working for LSN is a great way to stay involved in that exciting space.

Gonzalo Fernandez-Miranda, CEO, CureAge Therapeutics



Gonzalo is an expert in company creation and innovation within the advanced therapies space. He is co-founder of three biotech companies focused on gene therapy and nanoparticle-based drug delivery: Ninevah Ltd, Nanobots SL, and CureAge Ltd. He was also involved in the early-stage management of an RNA therapeutics company, Aptadel SL. Over the past five years, Gonzalo has held CSO and COO roles, gaining experience in R&D strategy, biotech management, fundraising, and licensing. He is currently the CEO of CureAge Therapeutics, a gene therapy company co-founded with Deep Science Ventures and the Children's Tumor Foundation. Gonzalo holds a PhD in Molecular Biology and has completed executive education at ESADE Business School.

Agnes Arbat, CEO, Oxolife



Agnes Arbat is the CEO of Oxolife and a medical doctor trained at the Universitat Autònoma de Barcelona (UAB), specializing in Clinical Pharmacology with executive training in GMP from IESE Business School. She has 14 years of experience in the pharmaceutical sector, including the last 10 years at Bayer, where she led the Medical Affairs and Medical Science Liaison teams for the Women's Health and Cardiovascular Therapeutic Areas. Agnes has a strong record of scientific contribution, with 10 indexed international papers, more than 30 communications at international conferences, and leadership of over 20 women's health clinical trials, including TEAM-09, REMO, APPROACH, and SEC-QoL. She has overseen more than 10 major product launches or new indication introductions. In addition to her industry leadership, Agnes is an invited professor and mentor in the Pharmaceutical & Biotech Master program at Universitat Pompeu Fabra (UPF).

Larry Raoul James, JD, MBA, Founder, President, and CEO, MindLab



Larry Raoul James, JD, MBA, has served as Founder, President, and CEO of MindLab since inception in 2013. He assembled a world-class team of employees, partners, consultants, and advisors and guided them through early drug development phases of compound development, patent approvals, animal and toxicology studies, and FDA meetings. Mr. James has 14 years of pain management experience as an attorney, a sales and marketing specialist, and a member of several pharma Executive Advisory Boards. He spent nearly a decade helping Endo Pharmaceuticals introduce several opioid analgesics to the market. Prior to his exclusive focus on pain management, Mr. James leveraged his entrepreneurial acumen across multiple industries; founding and growing firms in the entertainment and real estate fields and leading them through multi-million dollar exits. Mr. James holds a law degree from Fordham Law School, and a MBA in Finance from NYU Stern School of Business.

Nick Sireau, CEO, Serenatis Bio



Nick Sireau, PhD, is the CEO and Chair of Trustees at the AKU Society, a patient group that helps people with AKU, a rare genetic disease affecting both his children. Nick is co-founder and Chair of Beacon, an organisation that helps all rare disease patient groups. He is the editor of 'Rare Diseases: Challenges and Opportunities for Social Entrepreneurs' (Greenleaf 2013) and of the 'Patient Group Handbook: A Practical Guide for Research and Drug Development' (Beacon 2016). Nick is co-founder and Chair of Orchard OCD, a medical charity that funds research into obsessive-compulsive disorder (OCD), a common yet debilitating mental health condition. He is also co-founder of Sirgatan Therapeutics, a biotech that focuses on new treatments for OCD, and of Sireau Labs, a biotech that is developing mRNA therapy for AKU and other rare genetic diseases.

2:00 PM | DESIGNING A SMARTER REGULATORY PATH TO FIRST IN HUMAN (FIH) STUDIES

Early regulatory planning can transform an IND/CTA program from a fragmented set of activities into a focused, credible, and fundable development pathway. This session will outline best practices across nonclinical, CMC, First-in-Human (FIH) clinical design, and regulatory strategy, with a special emphasis on how early regulatory alignment drives integration and accelerates decision making. We will highlight some common pitfalls on the pathway to IND/CTA and attendees will gain actionable approaches to building an optimal regulatory strategy that meets business objectives, enabling a more predictable and efficient path to First-in-Human studies.

Geoff Fatzinger, Vice President, Regulatory Strategy, Certara



Geoff brings 20+ years of expertise and a demonstrated record of regulatory and business accomplishments covering the United States, Europe and Asia Pacific where he has served as a subject matter expert (SME) Reviewer and Commentator on New and Advanced Technologies for various agencies and continues to do so today. His experience spans national regulatory bodies world-wide, including the FDA in the US, as well as agencies in China and Japan. His team advises both big pharma teams and biotech startups as well as governmental entities, providing them expertise to help navigate regulatory challenges-whether current or anticipated-while providing a global regulatory perspective to guide the best path forward. Mr. Fatzinger is the Vice President, Regulatory Strategy, Certara, responsible for providing strategic regulatory oversight to product development and commercialization. Geoff is a highly experienced, results-oriented global regulatory professional, with very strong strategic capabilities and a very solid technical background that has allowed him to lead companies and projects to new levels of success in a variety of highly competitive industries, cutting-edge markets, and fast-paced environments.



3:00 PM | NAVIGATING REGULATORY PATHWAYS FOR EARLY-STAGE INNOVATION

Bringing a novel medical technology to market requires more than great science, it demands a clear understanding of regulatory frameworks. This session explores the EU and UK regulatory landscapes for early-stage innovations, highlighting common pitfalls that can delay approval and strategies to accelerate market access. Attendees will gain practical insights into planning for compliance from the outset, leveraging regulatory pathways effectively, and avoiding costly missteps.

Key Takeaways:

- Understand EU and UK regulatory requirements for early-stage MedTech and Biotech products
- Identify common challenges and how to mitigate them
- Learn strategies to streamline approval and reduce time-to-market

Luis Lopez-Navas, Senior Regulatory Consultant, DLRC



Luis is a Senior Regulatory Consultant and joined DLRC in May 2021 after 4 years at Andalusian Network for Design and Translation of Advanced Therapies, where he had some exposure to non-clinical regulatory. He has a strong track record in managing complex regulatory submissions and strategic interactions with both EU and US regulatory authorities. He has extensive experience in authoring and managing regulatory documents, including MAA and BLA dossiers, scientific advice packages, Orphan Drug Designations (ODDs), and FDA briefing books. Luis has a Master's in Manufacturing of Advanced Therapy Medicinal Products, an MSc in Tissue Engineering and a BSc & MSc in Biotechnology (5-year programme). He was recognised as a finalist for the TOPRA Awards for Regulatory Excellence in 2022. Luis is known for his analytical approach, collaborative mindset, and commitment to quality.

4:00 PM | VENTURE VALUATION WORKSHOP COMPANY VALUATION FOR FUNDRAISING

Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, its important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don'ts when speaking with investors and look at how to value a life science company with no revenues.

Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland



Dr. Patrik Frei is the founder and CEO of Venture Valuation AG, a company he established in 1999 to provide independent valuation services for high-growth industries. His first client was Novartis Venture Fund, and he has since conducted over 450 valuations for investors, biotech, pharma, and medtech companies. Patrik earned his degree from the University of St. Gallen and completed his PhD at EPFL Lausanne, focusing on the assessment and valuation of high-growth companies. He has served on the boards of Ineo, Aventron AG, and Ophthalmopharma, where he successfully out-licensed a portfolio of products. His articles have been published in journals such as "Nature Biotechnology" and "Chimia," and he has authored business publications. Dr. Frei also lectures on valuation at institutions like Seoul National University, EPFL Lausanne, and the University of St. Gallen, offering workshops globally.



MEDIA PARTNERS

